Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C3H7O6P.2Na.5H2O |
| Molecular Weight | 306.1138 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.[Na+].[Na+].OCC(CO)OP([O-])([O-])=O
InChI
InChIKey=PEMUISUYOHQFQH-UHFFFAOYSA-L
InChI=1S/C3H9O6P.2Na.5H2O/c4-1-3(2-5)9-10(6,7)8;;;;;;;/h3-5H,1-2H2,(H2,6,7,8);;;5*1H2/q;2*+1;;;;;/p-2
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C3H9O6P |
| Molecular Weight | 172.0737 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/ppa/sodium-glycerophosphate-pentahydrate.html | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | http://www.medsafe.govt.nz/profs/Datasheet/g/Glycophosinf.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/573222 | https://www.ncbi.nlm.nih.gov/pubmed/22961670 | https://www.ncbi.nlm.nih.gov/pubmed/15265286https://www.ncbi.nlm.nih.gov/pubmed/19275097 | https://www.ncbi.nlm.nih.gov/pubmed/929612 | https://www.ncbi.nlm.nih.gov/pubmed/4140270 | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | https://www.ncbi.nlm.nih.gov/pubmed/22383088
Sources: https://www.drugs.com/ppa/sodium-glycerophosphate-pentahydrate.html | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | http://www.medsafe.govt.nz/profs/Datasheet/g/Glycophosinf.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/573222 | https://www.ncbi.nlm.nih.gov/pubmed/22961670 | https://www.ncbi.nlm.nih.gov/pubmed/15265286https://www.ncbi.nlm.nih.gov/pubmed/19275097 | https://www.ncbi.nlm.nih.gov/pubmed/929612 | https://www.ncbi.nlm.nih.gov/pubmed/4140270 | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | https://www.ncbi.nlm.nih.gov/pubmed/22383088
Sodium glycerol 2-phosphate (Disodium beta-glycerophosphate) is used for the preparation of thermo-sensitive chitosan hydrogen as a scaffold to construct tissue engineered injectable nucleus pulposus (NP). Since Sodium glycerol 2-phosphate (6 g/day) reduced the lithogenic index of
bile in human subjects with cholesterol gallstones in a short-term study
and facilitated dissolution of cholesterol gallstones in mice, Sodium glycerol 2-phosphate may have potential to help dissolve cholesterol gallstones
in man. Sodium glycerol 2-phosphate is an alkaline phosphate inhibitor. Sodium β-glycerophosphate pentahydrate is used as a phosphatase inhibitor. It promotes bone matrix mineralization while delivering to osteoblasts by providing a source of phosphate ions. It is used in the development of hydrogels and scaffolds, which finds applications in tissue engineering and cell growth. It is used as an additive in isolation mediums by providing phosphate ions to isolate. It is utilized to promote mineralization in vitro by modulating bone cell metabolic activity.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL5979 |
|||
Target ID: Protein phosphatase |
|||
Target ID: Glycerol-2-phosphatase |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Glycophos Approved UseGlycophos is indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate. |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of oral administration of 'essential' phospholipid, beta-glycerophosphate, and linoleic acid on biliary lipids in patients with cholelithiasis. | 1979 |
|
| Pericytes derived from the retinal microvasculature undergo calcification in vitro. | 1990 Nov |
|
| Mechanism of action of beta-glycerophosphate on bone cell mineralization. | 1992 Oct |
|
| Biomimetic apatite coatings on micro-arc oxidized titania. | 2004 Aug |
|
| Bone regeneration by grafting of cultured human bone. | 2004 May-Jun |
|
| Enhancing effect of daidzein on the differentiation and mineralization in mouse osteoblast-like MC3T3-E1 cells. | 2006 Aug |
|
| Antibacterial properties of Ag (or Pt)-containing calcium phosphate coatings formed by micro-arc oxidation. | 2009 Jan |
|
| [Comparison study on injectable tissue engineered nucleus pulposus constructed by different cells and chitosan hydrogel]. | 2010 Jul |
|
| Taurine suppresses osteoblastic differentiation of aortic valve interstitial cells induced by beta-glycerophosphate disodium, dexamethasone and ascorbic acid via the ERK pathway. | 2012 Oct |
|
| Generation of osteogenic construct using periosteal-derived osteoblasts and polydioxanone/pluronic F127 scaffold with periosteal-derived CD146 positive endothelial-like cells. | 2013 Apr |
|
| The extracellular matrix protein Edil3 stimulates osteoblast differentiation through the integrin α5β1/ERK/Runx2 pathway. | 2017 |
|
| Bone regeneration with osteogenic matrix cell sheet and tricalcium phosphate: An experimental study in sheep. | 2017 Oct 18 |
|
| Alendronate-loaded, biodegradable smart hydrogel: a promising injectable depot formulation for osteoporosis. | 2018 Aug |
|
| In vitro and in vivo acute response towards injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofiber hydrogel. | 2018 Jan 15 |
Sample Use Guides
Dose
Adults:
The recommended dosage is individual. The recommended daily dosage of
phosphate during intravenous nutrition would normally be 10-20 mmol. This can be
met by using 10-20 mL of GLYCOPHOS (Sodium glycerophosphate pentahydrate) added to the infusion solution or to the
admixture for which compatibility has been proved.
Children, Infants and Neonates:
The recommended dosage is individual. The recommended dose for children,
infants and neonates is 1.0-1.5 mmol/kg body weight/day.
Method of administration
Intravenous Infusion.
GLYCOPHOS must not be given undiluted. The infusion time should not be less than 8 hours.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:44:31 GMT 2023
by
admin
on
Sat Dec 16 10:44:31 GMT 2023
|
| Record UNII |
5JIY5MMX0E
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2735049
Created by
admin on Sat Dec 16 10:44:31 GMT 2023 , Edited by admin on Sat Dec 16 10:44:31 GMT 2023
|
PRIMARY | |||
|
154804-51-0
Created by
admin on Sat Dec 16 10:44:31 GMT 2023 , Edited by admin on Sat Dec 16 10:44:31 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
5JIY5MMX0E
Created by
admin on Sat Dec 16 10:44:31 GMT 2023 , Edited by admin on Sat Dec 16 10:44:31 GMT 2023
|
PRIMARY | |||
|
13408-09-8
Created by
admin on Sat Dec 16 10:44:31 GMT 2023 , Edited by admin on Sat Dec 16 10:44:31 GMT 2023
|
PRIMARY | |||
|
DTXSID60158536
Created by
admin on Sat Dec 16 10:44:31 GMT 2023 , Edited by admin on Sat Dec 16 10:44:31 GMT 2023
|
PRIMARY | |||
|
69881-75-0
Created by
admin on Sat Dec 16 10:44:31 GMT 2023 , Edited by admin on Sat Dec 16 10:44:31 GMT 2023
|
ALTERNATIVE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE |
